EGFR and cancer: An exciting, novel concept in cancer chemoprevention may be the use of combination therapy, which may allow dose reduction (and hence decreased systemic bioavailability) of NSAIDs or coxibs when combined with other anti-cancer agents, e.g., epidermal growth factor receptor inhibitors.